

---

## The Pezcoller Foundation Symposia

XIV Pezcoller Symposium:

### The Novel Dichotomy of Immune Interaction with Tumors

May 30 – June 1, 2002 Trento, Italy

---

*Co-chairs:*

D.Hanahan, A.Lanzavecchia and E.Mihich

*Program Committee Members:*

Z.Werb and J.Allison

---

The main focus of the Symposium will concern a dichotomy, in that component cell types of the innate and antigen-specific immune system can have tumor-favoring as well as antagonistic (therapeutic) interactions with tumors. Topics to be considered include: the relationship of inflammation to tumor progression or destruction; mechanisms of antigen presentation as related to tumor escape; modifiers of lymphocyte migration and barriers to immune cell infiltration of tumors; the function of immune cells as amplifiers of carcinogenesis; the involvement of matrix metalloproteinases, cytokines/chemokines and their receptors in tumor progression; and the roles and potential uses of dendritic cells. A roundtable discussion of clinical perspectives in chemoprevention and immunoprevention will conclude the Symposium, with a particular focus on the prospects for achieving efficacious tumor killing by the immune system while inhibiting its proactive contributions to tumor growth, angiogenesis and metastasis.

As is traditional for these Symposia, each 30 minute presentation will be followed by a discussion period of equal time, this favouring interactions and cross-stimulation among participants in the meeting. A poster session will focus on the scientific themes discussed at the Symposium.

### Program:

#### Thursday, May 30, 2002

8:30	<b>Registration</b>	
9:00	<b>Pezcoller Foundation Officers</b>	<b>Welcome &amp; Introductory Remarks</b>
9:15	<b>Enrico Mihich</b>	<b>Focus &amp; Goals</b>

#### **AM, Session I, Antitumor and Tumor Favoring, Effects/Effectors**

Co-Chairs: Hans Schreiber and Simon Gordon

9:30	Alberto Mantovani	Tumor associated macrophages and dendritic cells
10:00	Discussion	
10:30	Coffee Break	
11:00	Ruth Ganss	Tumor endothelium as a barrier to infiltration
11:30	Discussion	
12:00	Antonio Lanzavecchia	How memories are kept in the immune system

12:30 Discussion

13:00 Lunch

### PM, Session II, Antitumor and Tumor Favoring, Effects/Effectors II

Co-Chairs: Soldano Ferrone and Gloria Heppner

14:00	Harvey Cantor	Regulation of Type 1 immunity and tumor rejection
14:30	Discussion	
15:00	Sharon Evans	Leukocyte-endothelial adhesion: Hot spots of the anti-tumor immune response
15:30	Discussion	
16:00	Coffee Break	
16:30	Dylan Daniel	Immunological enhancement of squamous carcinogenesis
17:00	Discussion	
17:30	Masuo Hosokawa	Malignant progression of murine fibrosarcoma cells by host inflammatory cells and its inhibition by BRMs
17:50	Discussion	
18:00	Adjourn	

### Friday, May 31, 2002

### AM, Session III, Chemokines in Tumor Biology

Co-Chairs: Doug Hanahan and Kurt Zanker

9:00	Robert Strieter	The role of CXC chemokines in angiogenesis and metastasis of cancer
9:30	Discussion	
10:00	Zena Werb	Matrix metalloproteinases: Mediators of inflammatory cell functions in neoplasia
10:30	Discussion	
11:00	Coffee Break	
11:30	Albert Zlotnik	Chemokines and cancer
12:00	Discussion	
12:30	General Discussion	
13:00	Lunch	
14:00	<b>Poster Session</b>	

### PM, Session IV, Biological Interactions

Co-Chairs: Eva Klein and Drew Pardoll

15:00	Olja Finn	Defined epithelial tumor antigens MUC1 and Cyclin B1 as cancer vaccines: An eye on prevention
15:30	Discussion	
16:00	Coffee Break	

16:30	Guido Forni	A limited autoimmunity to p185neu positive cells saves mice
17:00	Discussion	genetically predestined to develop multifocal and aggressive Her-2/neu mammary carcinomas
17:30	Kari Alitalo	Lymphangiogenesis and metastasis
18:00	Discussion	
18:30	General Discussion	
19:00	Adjourn	

**Saturday, June 1, 2002**

**AM, Session V, Clinical Perspectives**

Co-Chairs: Francesco Marincola and Giorgio Parmiani

8:30	Robert Schreiber	IFN- $\gamma$ , lymphocytes and cancer immunoediting
9:00	Discussion	
9:30	Jim Allison	Removing the brakes: Augmenting T-cell responses in
10:00	Discussion	tumor therapy in mice and man
10:30	Coffee Break	
11:00	Round Table Discussion	D. Hanahan, Chairman How to achieve tumor cell killing by the immune system while inhibiting its proactive contributors
12:00	Lunch	
13:30	Adjourn	